CONSTITUENT REPORT
trans-alpha-Bergamotene
trans-alpha-Bergamotene is a bergamotane-type sesquiterpene hydrocarbon that appears across copaiba, opopanax, carrot seed, basil, and a wider set of plant, fungal, and insect volatile systems. The live evidence base is strongest for identity, natural occurrence, and biosynthetic or ecological function rather than for direct human-use pharmacology. A recent bergamotene review describes alpha-trans-bergamotene as the most abundant bergamotene framework in nature, but constituent-specific therapeutic or safety evidence remains thin, so AromaForge should frame it primarily as a chemistry and aroma marker with cautious preclinical context.
Chemical identity and composition
NIST and PubChem identify trans-alpha-bergamotene as C15H24 and distinguish it from the cis isomer by stereochemical registry data and InChIKey. The reviewed bergamotene literature treats alpha-trans-bergamotene as a common natural bergamotene scaffold in plants, insects, and fungi, while archive GC-MS records place it in sesquiterpene-rich balsamic and woody oils including opopanax and copaiba.
Aroma and practical use
- Use the recorded woody, warm, balsamic, terpenic descriptors to explore a blend's scent character; perceived strength also depends on the other ingredients.
- Review the flagged use concerns across every contributing oil and the selected dilution.
- Read the route, preparation and experimental context before using a study finding to choose an oil.
Reported benefits and effects
Findings retain their study context. An animal or laboratory result describes that experiment.
A 2024 review identifies alpha-trans-bergamotene as the most abundant bergamotene reported in nature.
The review abstract states that bergamotenes occur in plants, insects, and fungi, with alpha-trans-bergamotene noted as the most abundant compound in that group.
This reference does not establish a therapeutic result or a safe use level for a custom oil blend.
A cotton terpene-synthase study functionally assigned GaTPS1 as a producer of (E)-alpha-bergamotene.
Europe PMC abstract data report that herbivore challenge induced TPS expression in Gossypium arboreum and that recombinant GaTPS1 was primarily responsible for producing (E)-alpha-bergamotene.
This reference does not establish a therapeutic result or a safe use level for a custom oil blend.
Archive-linked GC-MS sources place trans-alpha-Bergamotene at notable levels in opopanax and copaiba balsam profiles.
Current archive source documents report trans-alpha-Bergamotene at 6.62% in opopanax and 4.53% in copaiba balsam, supporting its practical role as a composition marker in sesquiterpene-rich oils.
This reference does not establish a therapeutic result or a safe use level for a custom oil blend.
Use concerns and concentration limits
Sensitization concernFlagged
Flagged in the constituent reference; assess the source, route and finished-product concentration.
Phototoxicity concernNot flagged
Not flagged in the current model. This is not proof of absence or unrestricted safety.
Oxidation concernNot flagged
Not flagged in the current model. This is not proof of absence or unrestricted safety.
Penetration enhancementNot flagged
Not flagged in the current model. This is not proof of absence or unrestricted safety.
A recorded constituent reference, not a recommended oil dilution. Product category, source applicability and all contributing oils must be checked before use.
unverified reference · No source provenance attachedNo constituent-specific public IFRA limit, RIFM monograph, or human tolerability study was verified for isolated trans-alpha-Bergamotene in this research pass.
This reference does not establish a therapeutic result or a safe use level for a custom oil blend.
No direct public citation is attached to this entry.
The accessible literature is weighted toward occurrence, ecological signaling, and biosynthesis rather than direct toxicology or clinical use.
This reference does not establish a therapeutic result or a safe use level for a custom oil blend.
No direct public citation is attached to this entry.
Broader claims about bergamotane bioactivity in review literature often refer to bergamotene-related structures as a class, not purified trans-alpha-Bergamotene alone.
This reference does not establish a therapeutic result or a safe use level for a custom oil blend.
No direct public citation is attached to this entry.
Constituents it may interact with
These are research candidates recorded in the interaction matrix. They do not add a proven-amplification bonus to the score.
TerpinoleneAmplification candidate
Candidate in the research matrix. A coefficient alone does not establish amplification at the dose, route or goal of your blend; no proven amplification is inferred from this row.
analytical · whole_oil
No source citation attached.
Read Terpinolene report →How the effects were investigated
terpene-synthase conversion of farnesyl diphosphate to (E)-alpha-bergamotene
Comparative transcriptome and heterologous-expression work in Gossypium arboreum identified a terpene synthase, GaTPS1, whose recombinant enzyme primarily produced (E)-alpha-bergamotene in vitro.
This reference does not establish a therapeutic result or a safe use level for a custom oil blend.
volatile emission during plant-pathogen interaction
A barley root interaction study found terpene-rich volatile shifts during fungal challenge, with trans-alpha-bisabolene and related sesquiterpenes appearing in the volatile set; this supports ecological volatile signaling context for this sesquiterpene class, though not a direct isolate mechanism for trans-alpha-Bergamotene alone.
This experimental finding does not establish benefit, dose or safety in people using this blend.
What this report cannot establish
- A reported constituent percentage does not establish an effective human therapeutic dose or the amount absorbed into the body.
- The presence of a constituent does not guarantee a clinical benefit, rash treatment or sleep improvement from a custom blend.
- An unflagged concern or missing use limit does not establish safety for ingestion, inhalation, skin exposure or a particular person.
- A candidate constituent interaction does not establish that two oils amplify one another at the selected proportions.
- Constituent descriptors alone do not establish a precise top, heart or base lifetime in a finished blend.
Known data gaps (7)
- This pass did not verify a constituent-specific human clinical study for isolated trans-alpha-Bergamotene.
- Public safety documentation specific to isolated trans-alpha-Bergamotene remains sparse despite broad bergamotene-class review coverage.
- Most accessible biological-activity discussion concerns bergamotane derivatives or class-level literature rather than purified trans-alpha-Bergamotene dose-response studies.
- Second-pass verification (2026-07-13): searched IFRA Standards Library, RIFM database, and FEMA flavor library by CAS 13474-59-4; FEMA listing found (flavor identity only, no dermal safety data). No IFRA standard or RIFM monograph specific to this isomer located. dermal_limit_pct and sensitizing remain unverified estimates; left unchanged.
- The numeric dermal reference lacks source provenance; a verified flag alone is insufficient.
- Some findings do not record an explicit exposure route; consult the linked study before applying them to a use.
- Interaction candidates lack an attached source citation and remain unqualified.